NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (TMCI, Financial) on behalf of Treace stockholders. Our investigation concerns whether Treace has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business."
Following this news, Treace's stock price fell by $6.95 per share, or approximately 62% on the same day.
If you purchased or otherwise acquired Treace shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com
